Guided ADHD Therapy for Managing the Extent and Severity of Symptoms

ADHD Clinical Trial

— GAMES  

Official title:

Guided ADHD Therapy for Managing the Extent and Severity of Symptoms - A Randomized, Controlled, Parallel-group, Intervention Study to Assess an At-home, Game-based Digital Therapy for Treating Adult Patients With Attention-Deficit/Hyperactivity Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05296473
• Other study ID #: CIP-013
• Status: Completed
• Phase: N/A
• Start date: May 5, 2022
• Est. completion date: March 12, 2024

Study information

• Verified date: March 2024
• Source: Lumos Labs, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 560
• Est. completion date: March 12, 2024
• Est. primary completion date: March 12, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 22 Years to 55 Years

Eligibility

Inclusion Criteria:

• Subjects 22-55 years of age

• Male or female

• Confirmed ADHD diagnosis, combined or inattentive type, at Screening based on DSM-5 criteria and established via the MINI-Adult, administered by a trained clinician

• Baseline score on the clinician-rated ADHD-RS total score =28

• Not undergoing pharmacological treatment with methylphenidate or amphetamine-based products at time of Screening; or, if undergoing pharmacological treatment, must be willing and appropriate (i.e., not optimally treated in the Investigator's judgement or having issues with tolerability) to wash out of current regimen

• Estimated IQ score =80 as assessed by the Kaufmann Brief Intelligence Test, Second Edition (KBIT-II)

• Ability to understand and speak English, follow written and verbal instructions (English), as assessed by the PI and/or Study Coordinator, and give informed consent (English)

• Have ability to connect wireless devices to a functional wireless network on a daily basis

• Ability to comply with all the testing and study requirements

Exclusion Criteria:

• Current, controlled (requiring restricted medication) or uncontrolled, comorbid psychiatric diagnosis, based on MINI-Adult and subsequent clinical interviewing, with significant symptoms including but not limited to posttraumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder, conduct disorder, or other symptomatic manifestations that in the opinion of the Investigator may confound study data/assessments.

• Patients who are currently treated with a non-stimulant medication for ADHD (i.e., atomoxetine, clonidine, guanfacine, viloxazine)

• Have previously been assessed by TOVA for potential enrollment in a clinical trial.

• Have previously used a videogame-like digital therapy (e.g., Akili EndeavorRxTM) OR Within the last three years, have used a cognitive or brain training platform (e.g., Peak, Brain HQ, Lumosity, Atentiv) for more than two weeks duration

• Known sensitivity to playing video games, such as headaches, dizziness, nausea.

• Initiation within the last 4 weeks of behavioral therapy or neurofeedback, or planned initiation during the study. Patients who have been in behavior therapy or neurofeedback consistently for more than 4 weeks may participate provided their routine is unchanged during the course of the study. Patients planning on changing or initiating behavior therapy or neurofeedback during the course of the study will be excluded.

• Patient is currently considered a suicide risk in the opinion of the Investigator, as measured by C-SSRS at screening (i.e., score of 4 or 5 on C-SSRS)

• Motor condition (e.g., physical deformity of the hands/arms; protheses) that prevents game playing as observed by the Investigator

• Recent history (within the past 12 months) of suspected alcohol or substance abuse or dependence

• Positive urine drug screen

• History of seizures (excluding febrile seizures), or significant motor or vocal tics, including but not limited to Tourette's Disorder and photo-sensitive epilepsy

• Visual acuity that cannot be corrected that prevents or negatively impacts game playing as observed by the Investigator

• Any use of psychoactive drugs (other than stimulant) that in the opinion of the Investigator may confound study data/assessments

• Has participated in a clinical trial within 90 days prior to screening

• Has a family member or close friend/associate also enrolled/currently participating in the same study

• Any other condition that in the opinion of the Investigator may confound study data/assessments

Related Conditions & MeSH terms

• ADHD

Intervention

Device:
• ADHD Therapy
investigational game-play therapy
• Control Therapy
control game-play therapy

Locations

Country	Name	City	State
United States	Center for Emotional Fitness	Cherry Hill	New Jersey
United States	FutureSearch Trials of Dallas	Dallas	Texas
United States	Duke University	Durham	North Carolina
United States	CNS Network	Garden Grove	California
United States	Center of Psychiatry and Behavioral Medicine	Las Vegas	Nevada
United States	Alivation Research, LLC	Lincoln	Nebraska
United States	Accel Research Sites - Maitland Clinical Research Unit	Maitland	Florida
United States	CNS Healthcare	Memphis	Tennessee
United States	Mindpath Care Centers	Raleigh	North Carolina
United States	University of California Davis MIND Institute	Sacramento	California
United States	Midwest Research Group	Saint Charles	Missouri
United States	University of California San Francisco	San Francisco	California
United States	Melmed Center	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Lumos Labs, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Test of Variables of Attention (TOVA®) Attention Comparison Score (ACS)	The TOVA is a standardized, computerized, continuous performance test (CPT). The TOVA Attention Comparison Score (ACS) is a comparison of a subject's scores to scores from a normative ADHD population. A score of < 0 indicates a subject's performance is similar to that of the normative ADHD population, with a lower score indicating a more severe ADHD profile. A positive change on the TOVA ACS from Day 0 to Day 63 indicates improvement.	Study Day 0 to Study Day 63
Secondary	ADHD-RS-5 Inattention Subscale with Adult Prompts	The ADHD-RS-5 with Adult Prompts is an 18-item, clinician-administered questionnaire that rates the frequency of occurrence of ADHD symptoms and behaviors as defined by criteria outlined for ADHD in the DSM-5. Each item is scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms). The first 9 items assess inattention symptoms and the last 9 items assess hyperactive-impulsive symptoms. Each subscale produces a sub-scale score ranging from 0-27. A higher subscale score indicates more severe ADHD symptoms and behaviors. A negative change on the inattention subscale from Day 0 to Day 63 indicates improvement.	Study Day 0 to Study Day 63
Secondary	Cambridge Brain Sciences Token Search	Token Search is a computerized task designed to assess working memory. In Token Search, subjects identify the location of a hidden token in a set of boxes while remembering where previous tokens have been found. Correctly finding a token in every box will increase difficulty level in the form of a new puzzle with an increased number of boxes. Performance is indicated by the average number of tokens found. A positive change in score on the Token Search task from Day 0 to Day 63 indicates improvement.	Study Day 0 to Study Day 63
Secondary	Cambridge Brain Sciences Spatial Span	Spatial Span is a computerized task designed to assess spatial short-term memory and based on the Corsi Block tapping task. In Spatial Span, subjects are shown a sequence of flashing boxes and have to repeat the sequence. Sequence lengths increase with correct answers. Performance is indicated by the average number of boxes remembered during the task. A positive change in score on the Spatial Span ask from Day 0 to Day 63 indicates improvement.	Study Day 0 to Study Day 63
Secondary	Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Working Memory and Inhibit Percentiles	The BRIEF-A is composed of 75 items within nine non-overlapping theoretically and empirically derived clinical scales that measure various aspects of executive functioning. Each item is rated as either 1 (never), 2 (sometimes), or 3 (often). A reduction in score from Day 0 to Day 63 indicates improvement.	Study Day 0 to Study Day 63
Secondary	Weiss Functional Impairment Rating Scale - Self-Report (WFIRS-S)	The WFIRS-S is a validated rating scale used to capture functional difficulties in the lives of individuals with ADHD in 7 domains. Each item is scored on a 4-point scale ranging from 0 (Never or not at all) to 3 (Very often of very much). A reduction in score from Day 0 to Day 63 indicates improvement.	Study Day 0 to Study Day 63
Secondary	Clinical Global Impression Scale - Improvement (CGI-I)	The Clinical Global Impression Scale-Improvement (CGI-I) is a clinician's comparison of the participant's overall clinical condition at follow-up to the overall clinical condition at baseline. The CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). A score of 1 (very much improved) or 2 (much improved) or 3 (minimally improved) would indicate overall improvement of ADHD severity.	at Study Day 63